1. Home
  2. XOMAO vs SPPL Comparison

XOMAO vs SPPL Comparison

Compare XOMAO & SPPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XOMAO
  • SPPL
  • Stock Information
  • Founded
  • XOMAO N/A
  • SPPL 2016
  • Country
  • XOMAO United States
  • SPPL Singapore
  • Employees
  • XOMAO 13
  • SPPL N/A
  • Industry
  • XOMAO Biotechnology: Pharmaceutical Preparations
  • SPPL
  • Sector
  • XOMAO Health Care
  • SPPL
  • Exchange
  • XOMAO Nasdaq
  • SPPL Nasdaq
  • Market Cap
  • XOMAO N/A
  • SPPL N/A
  • IPO Year
  • XOMAO N/A
  • SPPL 2023
  • Fundamental
  • Price
  • XOMAO $25.26
  • SPPL $2.67
  • Analyst Decision
  • XOMAO
  • SPPL
  • Analyst Count
  • XOMAO 0
  • SPPL 0
  • Target Price
  • XOMAO N/A
  • SPPL N/A
  • AVG Volume (30 Days)
  • XOMAO N/A
  • SPPL 16.9K
  • Earning Date
  • XOMAO N/A
  • SPPL 01-01-0001
  • Dividend Yield
  • XOMAO N/A
  • SPPL N/A
  • EPS Growth
  • XOMAO N/A
  • SPPL N/A
  • EPS
  • XOMAO N/A
  • SPPL N/A
  • Revenue
  • XOMAO N/A
  • SPPL $2,764,846.00
  • Revenue This Year
  • XOMAO N/A
  • SPPL N/A
  • Revenue Next Year
  • XOMAO N/A
  • SPPL N/A
  • P/E Ratio
  • XOMAO N/A
  • SPPL N/A
  • Revenue Growth
  • XOMAO N/A
  • SPPL N/A
  • 52 Week Low
  • XOMAO N/A
  • SPPL $2.02
  • 52 Week High
  • XOMAO N/A
  • SPPL $16.80
  • Technical
  • Relative Strength Index (RSI)
  • XOMAO 53.03
  • SPPL 31.66
  • Support Level
  • XOMAO $25.10
  • SPPL $2.18
  • Resistance Level
  • XOMAO $25.30
  • SPPL $3.28
  • Average True Range (ATR)
  • XOMAO 0.11
  • SPPL 0.32
  • MACD
  • XOMAO 0.02
  • SPPL -0.06
  • Stochastic Oscillator
  • XOMAO 73.81
  • SPPL 30.49

About XOMAO AGNC Investment Corp.

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.

Share on Social Networks: